Tlouštíci jako skvělí milenci, návrat ztracené kosti i nově objevený orgán Lidské tělo stále překvapuje vitalia.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vitalia.cz Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Previously only suspected, now made it visible thanks to the molecular reporter: where human tumor cells and brain cells of a mouse meet, the tumor cells have a different identity. view more
Credit: Gargiulo Lab, MDC
Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year. The diagnosis amounts to a death sentence: Even after surgical resection followed by radiation and chemotherapy, the glioblastoma will kill the patient in a few months. This is because the tumor invariably returns after treatment, and in a more aggressive form than before.
Molecular reporters produce fluorescence to expose the allies of tumor cells
Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year. The diagnosis amounts to a death sentence: Even after surgical resection followed by radiation and chemotherapy, the glioblastoma will kill the patient in a few months. This is because the tumor invariably returns after treatment, and in a more aggressive form than before.
Researchers investigating glioblastoma tissue always find immune cells inside the tumor. They have therefore long suspected that these cells strengthen the tumor, instead of fighting it. A team led by Dr. Gaetano Gargiulo at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) has now supplied direct evidence of this.
Heterogeneity in quality of life of long‐term colon cancer survivors: a latent class analysis of the population‐based PROFILES registry wiley.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wiley.com Daily Mail and Mail on Sunday newspapers.
Study sheds new light on immune system interactions with cancer
Cancers like melanoma are hard to treat, not least because they have a varied bag of tricks for defeating or evading treatments.
A combined research effort by scientists at the Weizmann Institute of Science and researchers in the Netherlands Cancer Institute in Amsterdam and the University of Oslo, Norway, shows exactly how tumors, in their battles to survive, will go so far as to starve themselves in order to keep the immune cells that would eradicate them from functioning.
The immunotherapies currently administered for melanomas work by removing obstacles that keep immune cells called T cells from identifying and killing tumor cells. Recent research suggested that in melanoma, another blocker could assist the T cells - this one to stop an enzyme called IDO1 that is overproduced by the cancer cells.